Monitor regulatory developments in the US regarding MDMA and psilocybin rescheduling, as this is critical for future market access. Track the company's ability to scale production and expand into new markets with the IPO proceeds. Watch for signs of improving gross margins as commercial sales grow.
Executive Summary
Optimi Health Corp., a Canadian psychedelic pharmaceutical manufacturer, is conducting an IPO to raise up to $15.8 million. The company holds key regulatory licenses allowing it to produce and export GMP-grade MDMA and psilocybin for therapeutic use in Australia, where it has commercial sales. The offering proceeds will fund production scaling, market expansion into Israel and the US, and general operations. Despite having revenue, the company has significant operating losses and faces substantial regulatory and market risks.
Key Financial Metrics
Key Facts
- Canadian psychedelic pharmaceutical company with GMP and Drug Establishment Licenses from Health Canada
- Products (MDMA and psilocybin) are commercially available in Australia under the Authorised Prescribers Scheme
- IPO to raise $12.3-$14.3 million (net) by offering 2.1-2.5 million shares at $6-$8 per share
- Proceeds will be used for scaling production (25.5%), market expansion to Israel/US (16%), and general working capital (58.5%)
- Company reported $426,301 revenue and $3.7 million net loss for the year ended September 30, 2025
- Significant risks include regulatory uncertainty, history of operating losses, and dependence on US rescheduling of Schedule I substances
Financial Impact
Raises $12.3-$14.3 million net proceeds; revenue of $426,301 with $3.7 million net loss in fiscal 2025
Risk Factors
- Regulatory risk: US rescheduling of Schedule I substances is uncertain and critical for market access
- Financial risk: Company has a history of operating losses and may need additional financing
- Market risk: Limited commercial track record and dependence on regulatory approvals in new markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001193125-26-106121 |
| Document: d43258dex11.htm | 0001193125-26-106121 |
| Document: d43258dex41.htm | 0001193125-26-106121 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $3.12 | awaiting T+5 | — | $3.04 (−2.56%) |
Oct 20, 2026 7d ago | 6-K | $3.36 $3.04 | ▼ −9.52% | ▼ −9.60% | $3.04 (−9.52%) |
Oct 7, 2026 20d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.04 (−24.75%) |
Oct 5, 2026 22d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.04 (−26.39%) |
Sep 29, 2026 28d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.04 (−36.40%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.04 (−38.71%) |
Sep 22, 2026 5w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.04 (−38.71%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.04 (−37.96%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.04 (−32.44%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.04 (+37.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers